Professor Paul Moss OBE FMedSci MB.BS PhD FRCPath

Professor Paul Moss

Institute of Immunology and Immunotherapy
Deputy Head of College of Medical and Dental Sciences
Professor of Haematology

Contact details

Institute of Immunology and Immunotherapy
University of Birmingham
Cancer Sciences Building
B15 2TT
What is the UK Coronavirus Immunology Consortium?

Paul Moss is Professor of Haematology within the Institute of Immunology and Immunotherapy at the University of Birmingham and Deputy Head of the College of Medical and Dental Sciences. He is an international figure in translational human immunology and an NIHR Senior Investigator. He was previously Chair of the Infection and Immunity Board at the Medical Research Council and also served as Chair of the Clinical and Translational Research Committee at Cancer Research UK.

Professor Moss led the UK Coronavirus Immunology Consortium (UK-CIC) that brought together leading immunologists from 20 UK universities to understand the immune response to SARS-CoV-2. UK-CIC launched in August 2020 with £6.5 million funding from UKRI and NIHR. It aimed to determine the mechanisms of virus-specific immunity and how these relate to clinical outcome in different patient groups. Published research support by UK-CIC can be viewed online.

He is currently leading the immunity strand of the COVID-19 National Core Studies Programme, initiated by Sir Patrick Vallance in October 2020, that supports research to improve our understanding of immunity against COVID-19.

As well as publishing in leading journals, including Nature, Blood and the European Journal of Immunology, Professor Moss's research has featured in the Financial Times, BBC News and The Economist.


  • M.A. Medical Sciences (University of Cambridge)
  • B.M. B.S. (University of Oxford)
  • Member of Royal College of Physicians UK
  • Fellow of Royal College of Pathologists
  • Ph.D
  • Fellow of the Academy of Medical Sciences
  • Order of the British Empire (OBE)


Teaching Programmes

Teaching Activity

Professor Moss makes substantial contributions to teaching both within the University of Birmingham and beyond. He was previously Programme Director of the Intercalated Bachelor in Medical Sciences (Clinical Sciences) which offered medical students the opportunity to undertake an eight month research project during their undergraduate degree.


Research Themes

Professor Moss’s research programme is based around the immunology of cancer, transplantation and viral infection. His team has an internationally competitive position in cytomegalovirus infection; bone marrow transplantation and cancer immunology. 

Research Activity

Professor Moss’s research is focussed around the application of translational immunological research in the study of human disease. His current research group includes clinical and non-clinical research scientists working on a range of different projects:

The immune response to cancer

The group study the innate, adaptive and stromal response in several human cancers, including leukaemia and lymphoma, as well as pancreatic, ovarian and testicular cancer. Important technologies include flow sorting, CyTOF and single cell RNA-Seq.

Immune control of human viral infection

With over 20 years of contribution within cytomegalovirus infection, the team continue to investigate the mechanisms and impact of chronic viral infection on human health. In recent years, Professor Moss has been making an extensive contribution to research related to the SARS-CoV-2 virus. 

Mechanisms of graft-versus-leukaemia following stem cell transplantation

Stem cell (bone marrow) transplantation can cure chemo-resistant cancer and the team are working with colleagues within the College of Medical and Dental Sciences to uncover the mechanisms of this effect.

Additional research is undertaken with Professor Tatjana Stankovic on the genetics of Chronic Lymphocytic Leukaemia and with colleagues within University Hospitals Birmingham NHS Foundation Trust on research using clinical informatics.

Professor Moss's work is supported by research programme grants and collaborations with industry. Several of his discoveries have been taken into clinical trials.

Professor Moss was a member of the UoA1 panel (Clinical Medicine) in REF 2021 and is on the Scientific Advisory Board for the MATWIN cancer open-innovation platform in France. 

Other activities

Clinical Activity/NHS Affiliation

Professor Moss is an Honorary Consultant at the University Hospitals Birmingham NHS Foundation Trust. His primary interests are in haemato-oncology and general haematology and he is the Clinical Service Lead for Chronic Lymphocytic Leukaemia. He became an NIHR Senior Investigator in 2018.

He is currently Chair of the UK Regenerative Medicine Platform. He is also Chair of the Innovate/MRC Biomedical Catalyst Major Awards Panel.

In addition he has previously held a number of important academic appointments:

  • Chair of the Infections and Immunity Board and member of Strategy Board at the Medical Research Council
  • Chair of the Cancer Research UK (CRUK) Clinical and Translational Research Committee (2008-2012)
  • Member of the Wellcome Trust Clinical Interview Committee


Recent publications


PHOSP-COVID study collaborative group & ISARIC4C Investigators 2024, 'Accelerated immune ageing is associated with COVID-19 disease severity', Immunity & Ageing, vol. 21, no. 1, 6.

Zhang, X, King, C, Dowell, A, Moss, P, Harper, L, Chanouzas, D, Ruan, X & Salama, AD 2024, 'CD36 regulates macrophage and endothelial cell activation and multinucleate giant cell formation in anti neutrophil cytoplasm antibody vasculitis', Clinical Immunology, vol. 260, 109914.

Verma, K, Croft, W, Greenwood, D, Stephens, C, Malladi, R, Nunnick, J, Zuo, J, Kinsella, FAM & Moss, P 2024, 'Early inflammatory markers as prognostic indicators following allogeneic stem cell transplantation', Frontiers in immunology, vol. 14, 1332777.

Abudu, O, Nguyen, D, Millward, I, Manning, JE, Wahid, M, Lightfoot, A, Marcon, F, Merard, R, Margielewska-Davies, S, Roberts, K, Brown, R, Powell-Brett, S, Nicol, SM, Zayou, F, Croft, WD, Pearce, H, Moss, P, Iqbal, AJ & McGettrick, HM 2024, 'Interplay in galectin expression predicts patient outcomes in a spatially restricted manner in PDAC', Biomedicine and Pharmacotherapy, vol. 172, 116283.

Dündar, NB, Sarphie, D, Yüce, K, Gaygısız, Ü, Kaskatı, OT, Türkoğlu, M, Bıkmaz, GA, Karabıyık, L, Çağlar, K, Bozdayı, G, Mian, R, Moss, P & İlhan, MN 2023, 'Assessing neutrophil-derived ROS production at the bedside: a potential prognostic tool in severe COVID-19 cases', Intensive Care Medicine Experimental, vol. 11, no. 1, 69.

Stirrup, O, Shrotri, M, Adams, NL, Krutikov, M, Nacer-Laidi, H, Azmi, B, Palmer, T, Fuller, C, Irwin-Singer, A, Baynton, V, Tut, G, Moss, P, Hayward, A, Copas, A & Shallcross, L 2023, 'Clinical Effectiveness of SARS-CoV-2 Booster Vaccine Against Omicron Infection in Residents and Staff of Long-term Care Facilities: A Prospective Cohort Study (VIVALDI)', Open Forum Infectious Diseases, vol. 10, no. 1, ofac694.

Loke, J, Upasani, V, Gaskell, C, Fox, S, Fletcher, R, Thomas, C, Hopkins, L, Kumari, A, Tang, T, Yafai, E, Boucher, R, Homer, V, Toth, A, Chan, YLT, Randall, K, Rider, T, O'nions, J, Drew, V, Pillai, A, Dungarwalla, M, Murray, D, Khan, A, Wandroo, F, Moore, S, Krishnamurthy, P, Huang, YJ, Knapper, S, Byrne, J, Zhao, R, Craddock, C, Parry, H, Moss, P, Stanworth, SJ & Lowe, DM 2023, 'Defective T‐cell response to COVID‐19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes', British Journal of Haematology, vol. 202, no. 3, pp. 498-503.

Ladhani, SN, Dowell, AC, Jones, S, Hicks, B, Rowe, C, Begum, J, Wailblinger, D, Wright, J, Owens, S, Pickering, A, Shilltoe, B, McMaster, P, Whittaker, E, Zuo, J, Powell, A, Amirthalingam, G, Mandal, S, Lopez-Bernal, J, Ramsay, ME, Kissane, N, Bell, M, Watson, H, Ho, D, Hallis, B, Otter, A, Moss, P & Cohen, J 2023, 'Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara-Bavaria Nordic vaccine against mpox in children: a national outbreak response', The Lancet Infectious Diseases, vol. 23, no. 9, pp. 1042-1050.

Verma, K, Croft, W, Pearce, H, Zuo, J, Stephens, C, Nunnick, J, Kinsella, F, Malladi, R & Moss, P 2023, 'Early expression of CD94 and loss of CD96 on CD8+ T cells after allogeneic SCT is predictive of subsequent relapse and survival', Haematologica, vol. 108, no. 2, pp. 433-443.

Stirrup, O, Shrotri, M, Adams, NL, Krutikov, M, Azmi, B, Monakhov, I, Tut, G, Moss, P, Hayward, A, Copas, A & Shallcross, L 2023, 'Effectiveness of successive booster vaccine doses against SARS-CoV-2 related mortality in residents of long-term care facilities in the VIVALDI study', Age and Ageing, vol. 52, no. 8, afad141.


Moss, P 2024, 'Ibrutinib reversal of immune exhaustion in CLL', Blood, vol. 143, no. 1, pp. 5-7.

Pather, S, Madhi, SA, Cowling, BJ, Moss, P, Kamil, JP, Ciesek, S, Muik, A & Türeci, Ö 2023, 'Corrigendum: SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines', Frontiers in immunology, vol. 14, 1232965.


Roberts, T, Uwenedi, G, Bruton, R, McIlroy, G, Damery, S, Sylla, P, Logan, N, Scott, S, Lau, M, Elzaidi, A, Plass, S, Mallick, S, Spencer, K, Stephens, C, Bentley, C, Pratt, G, Zuo, J, Paneesha, S, Willett, B, Moss, P & Parry, H 2024, 'Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia', Blood Cancer Journal, vol. 14, no. 1, 22.

Farhat, M, Croft, W, Parry, HM, Verma, K, Kinsella, FAM, Xu, J, Bone, D, McSkeane, T, Paneesha, S, Pratt, G, Moss, P & Zuo, J 2024, 'PD-1 expression contributes to functional impairment of NK cells in patients with B-CLL', Leukemia.

Review article

Halle-Smith, JM, Pearce, H, Nicol, S, Hall, LA, Powell-Brett, SF, Beggs, AD, Iqbal, T, Moss, P & Roberts, KJ 2024, 'Involvement of the Gut Microbiome in the Local and Systemic Immune Response to Pancreatic Ductal Adenocarcinoma', Cancers, vol. 16, no. 5, 996.

View all publications in research portal



Immune response to cancer; immunity to viruses and related health problems; evolution in clinical medicine.


Immune response; vaccinations.

Media experience

Multiple national and international media have quoted Professor Moss, including BBC News, The Economist, Reuters, The Guardian, and the Financial Times. Professor Moss has also delivered several press meetings through the Science Media Centre regarding the SARS-CoV-2 virus. 

Alternative contact number available for this expert: contact the press office



Cancer, including immune response to cancer and evolution in clinical medicine.